AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Daily Turnover | The turnover of Abbvie on 7/11 was $959.92 Million, Ranking 75
ByAinvest
Friday, Jul 11, 2025 6:00 pm ET1min read
The turnover of Abbvie on 7/11/2025 was $959.92 million, ranking 75 in today's market, the Volume is 4.99 million.
Abbvie(ABBV) shares closed at $192.45, down 1.31% on 7/11/2025, up 1.67% in the last 5 trading days, up 3.68% this month, up 8.30% year-to-date and up 13.02% in the last 52 weeks.
*If the company has been listed for less than 52 weeks, the 52-week gain is the gain since the listing.
(The same applies for less than 1 month, or less than 5 trading days)
【History Turnover】
| Date | Turnover | Volume | Price | Performance |
|---|---|---|---|---|
| 7/11/2025 | $959.92 million | 4.99 million | $192.45 | -1.31% |
| 7/10/2025 | $1179.44 million | 6.05 million | $195 | 2.30% |
| 7/9/2025 | $1063.87 million | 5.59 million | $190.62 | 0.45% |
| 7/8/2025 | $1351.12 million | 7.11 million | $189.77 | 1.14% |
| 7/7/2025 | $2079.12 million | 11.05 million | $187.63 | -0.87% |
【Company Profile】
Abbvie Inc. was incorporated in Delaware on April 10, 2012 to hold Abbott's former research-based pharmaceuticals business. The company is a global, research-based biopharmaceutical company. AbbVie develops and markets advanced therapies that address some of the world's most complex and serious diseases. AbbVie's products are focused on treating conditions such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease; low testosterone; HIV; endometriosis; thyroid disease; Parkinson's disease; and complications associated with chronic kidney disease and cystic fibrosis, among health conditions. AbbVie's pipeline of promising new medicines includes more than 20 compounds or indications in Phase II or Phase III development across such important medical specialties as immunology, virology, oncology, renal disease, neurological diseases and women's health.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet